Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2012 Results
Date:11/7/2012

/p>

-5 

Select Balance Sheet Data1 September 30June 30September 30(in thousands)201220122011Total cash and marketable securities

$ 134,404$ 144,701$ 180,459  

(1) Unaudited
(2) Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses OPERATIONAL HIGHLIGHTS
The tasimelteon Non-24 program continues towards the goal of a projected mid-2013 NDA filing with the FDA.  Vanda is in continuing discussions with the FDA to confirm the path and requirements for this regulatory submission, and while no agreement has been reached with the agency, the FDA has suggested that Vanda present its Non-24 study results to further the discussions.  The SET and RESET Phase III efficacy studies for Non-24 are both fully enrolled.  Vanda expects to report top-line results for the SET study by the end of 2012 and to report top-line results for the RESET study in the first quarter of 2013.In October 2012, Vanda announced that tasimelteon was shown for the first time to restore daily cortisol rhythms in totally blind patients suffering from Non-24.  Tasimelteon's effect has now been demonstrated on both melatonin and cortisol circadian rhythms, which further supports its potential to reset the master body clock.  This observation was made during an open-label screening segment of the RESET study.  Tasimelteon has the potential to be the first pharmaceutical product to address the circadian dyssynchrony which is definitional for Non-24.

The tasimelteon MAGELLAN Phase IIb/III efficacy study for MDD is fully enrolled and Vanda expects to report top-line results in the first quarter of 2013.  

The review of Vanda's Marketing Authorization Application for oral iloperidone tablets in the European Union is ongoing. Vanda is preparing for an expected oral hearing in November 2012 as it continues to evaluate its European strate
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
2. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
3. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
4. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
5. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
6. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
7. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
8. Vanda Pharmaceuticals Reports First Quarter 2012 Results
9. Radiopharmaceuticals and Contrast Media: Frost & Sullivan Predicts Market Growth in Europe
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
11. Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... -- Biomedical Research Laboratories (BRL) ( www.brlscience.com ) announced ... 2014 Inc. 500 list of America,s fastest-growing companies. ... prestigious list and ranked among the most successful companies ... Laboratories, CEO. "Today,s announcement represents a major milestone for ... work and talent of our team. BRL has a ...
(Date:8/26/2014)... Mass. , Aug. 26, 2014 Acelleron Medical ... Eatontown, N.J ., is expanding.  Acelleron, a ... to form a new division, Acelleron Maternal Health & Wellness ... clients by providing a full range of resources for pregnant ... has been named the director of maternal wellness. Vecchi, the ...
(Date:8/26/2014)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and its associated pain, ... advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) ... more than 100,000 Americans. As this disease progresses, ... lose the ability to breathe, leading ultimately to ...
Breaking Medicine Technology:Biomedical Research Laboratories Named to Inc. 500 List of America's Fastest-Growing Companies 2Suzanne Vecchi Named Director of Newly Acquired Acelleron Maternal Health & Wellness 2Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 2Sorrento Awarded NIH Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF) 3
... DATATRAK International, Inc. (OTCQX: DATA), a technology and services ... trials industry, today announced that it has been awarded ... Organization (CRO) in India, with which the Company had ... order to execute a Phase II study for the ...
... 8, 2011 Vanda Pharmaceuticals Inc. (Nasdaq: ... has granted orphan drug designation for tasimelteon, an oral ... for Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals with ... the designation that the Committee for Orphan Medicinal Products ...
Cached Medicine Technology:DATATRAK Awarded First Study With Kreara Solutions 2DATATRAK Awarded First Study With Kreara Solutions 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 2Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 4
(Date:8/26/2014)... Hearing aids are not always covered ... holders to determine what their hearing care benefits are. ... health plans and has published benefit details on their website ... , The following is a list of insurances or agencies ... NYSHIP/ NYS Empire Plan - Hearing Aid Benefit is $1500 ...
(Date:8/26/2014)... August 27, 2014 Emerging and established ... and useful to those they serve – which includes ... blog at http://www.PerWickstrom.com and read his latest ... Leaders Maintain their Edge.” , “Leadership is ... and can therefore be assumed,” commented Per Wickstrom, who ...
(Date:8/26/2014)... August 27, 2014 There are a ... however the reality is cruel. Some people, especially ladies ... may not save enough money to be affluent. Today, ... delighted to announce its new catalog, Flash Deals (also ... bags, outdoor accessories and more from this company are ...
(Date:8/26/2014)... 27, 2014 Atlanta Hearing Associates ... Hearing Associates has expanded its professional staff to 6 audiologists. ... Stephanie Collins . Atlanta Hearing Associates prides itself ... display a passionate commitment to patient needs and keep themselves ... loss treatments. The practice has grown from 1 to 4 ...
(Date:8/26/2014)... (PRWEB) August 27, 2014 Private ... custom labeled nutritional dietary supplements and products has ... their 33rd annual Inc. 500|5000 list. This exclusive ... marks the second consecutive year for Private Label ... Dell, Yelp, GoPro, Bridger, Tough Mudder, Bowlmor and ...
Breaking Medicine News(10 mins):Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 2Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 3Health News:Per Wickstrom’s Latest Blog Post Provides 10 Tips to Help Leaders Maintain their Edge 2Health News:Become a Rich Person Right Away By Taking Advantage Of Fecbek.com's Flash Deals 2Health News:Atlanta Hearing Associates Needs New Audiologists to Its Professional Staff 2Health News:Atlanta Hearing Associates Needs New Audiologists to Its Professional Staff 3Health News:Private Label Nutraceuticals Honored by Inc. 5000 as One of Today’s Fastest Growing Private Companies in America with Three-Year Sales Growth of 620% 2Health News:Private Label Nutraceuticals Honored by Inc. 5000 as One of Today’s Fastest Growing Private Companies in America with Three-Year Sales Growth of 620% 3Health News:Private Label Nutraceuticals Honored by Inc. 5000 as One of Today’s Fastest Growing Private Companies in America with Three-Year Sales Growth of 620% 4
... poses dangers, researchers say , , TUESDAY, Dec. 23 (HealthDay ... adults in the United States combine over-the-counter medications with ... for potentially dangerous interactions, a new survey finds. , ... for more than 175,000 emergency department visits for adverse ...
... doesn,t fund procedure , , TUESDAY, Dec. 23 (HealthDay ... each year, because their states don,t cover the procedure ... case to be made that circumcisions can protect our ... of public policy at the University of California, Los ...
... major tissue damage or surgical intervention is an important ... established therapeutic measure for severe liver diseases, it would ... the regenerative process and if they depend on the ... The group led by Prof. Schlaak from the Department ...
... It might be possible to grow human blood ... new study at The Ohio State University Medical Center. ... issue of the journal Experimental Hematology , might ... and in quantities that can ease the chronically tight ...
... the mutation faced higher odds of heart attack, death, study ... variation can make younger heart attack patients more prone to ... receive the anti-clotting drug Plavix, researchers report. , The study ... The Lancet . , Plavix plus low-dose aspirin are often ...
... LANSING, Mich. Only 3 percent of kids, meals ... the first study to examine the nutrient quality of ... Michigan State University,s Sharon Hoerr, a food science and ... teamed up with economist Sharon O,Donnell and pediatrician Jason ...
Cached Medicine News:Health News:Drug Combinations Putting Seniors at Risk 2Health News:Drug Combinations Putting Seniors at Risk 3Health News:Drug Combinations Putting Seniors at Risk 4Health News:Circumcision Rates Too Low 2Health News:Molecular events involved in liver regeneration 2Health News:Bioreactors might solve blood-platelet supply problems 2Health News:Gene Ups Risk for Those on Blood-Thinner Plavix 2Health News:Gene Ups Risk for Those on Blood-Thinner Plavix 3Health News:Nutritious fast-food kids' meals are scarce, researchers find 2
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The CA method used on the Dade Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of calcium in serum....
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
Medicine Products: